Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

October 16, 2019October 16, 2019

Oral Anticoagulant Dabigatran Prevented Memory Loss in Mouse Model of Alzheimer’s, Study Shows

News

Oral treatment over one year with an approved blood thinner called dabigatran prevented memory loss, preserved blood circulation in the brain and reduced the amount of senile plaques in ... Read more

October 9, 2019October 9, 2019

NDX-1017 Phase 1 Trial Complete, Results Will Be Presented at CTAD Conference, Athira Says

News

Athira Pharma has completed the Phase 1 trial testing NDX-1017, its lead therapeutic candidate for Alzheimer’s disease, and will present the results at the 12th Annual Clinical Trials on Alzheimer’s ... Read more

October 2, 2019October 2, 2019

Carefully Targeting Brain Immune Cells May Help Prevent Amyloid-beta Plaques, Study Suggests

News

Therapeutics that target brain immune cells known as microglia may prevent the formation of amyloid-beta plaques, one of the hallmarks of Alzheimer’s disease, according to a recent mouse study. ... Read more

September 23, 2019September 23, 2019

Phase 3 Trials of Elenbecestat in Early Alzheimer’s Stopped for Lack of Benefit, Eisai and Biogen Say

News

Two global Phase 3 clinical trials — MISSION AD1 (NCT02956486) and MISSION AD2 (NCT03036280) — evaluating elenbecestat as a potential therapy for early Alzheimer’s disease are being stopped early, Eisai and Biogen announced. This ... Read more

September 20, 2019September 20, 2019

Alzheimer’s Vaccine Found Safe, Effective in Patients with Mild Forms of the Disease, Phase 2 Study Finds

News

AXON Neuroscience’s investigational AADvac1 vaccine against tau protein, a hallmark of Alzheimer’s disease, was found safe and effective at lessening signs of neurodegeneration in patients with mild Alzheimer’s, according ... Read more

August 30, 2019August 30, 2019

3D Model Unravels How Beta-amyloid Weakens Brain-Blood Barrier, May Aid in Treatment Discovery

News

A new 3D model using human cells grown on a chip can mimic what happens in the brain during Alzheimer’s and allow for the screening of possible therapies in ... Read more

August 23, 2019August 23, 2019

Diet Rich in Choline Aids Memory and Lowers Risk of Dementia, Study Suggests

News

A diet rich in phosphatidylcholine, a form of the choline found in foods like eggs and meat, was linked to a lower risk of dementia and better memory skills in ... Read more

August 16, 2019

Protein Treatment, GRF6019, Seen to Help Maintain Cognition in Alzheimer’s Patients in Phase 2 Trial

News

Alkahest’s experimental blood-derived protein GRF6019 helps maintain cognition and function in mild to moderate Alzheimer’s disease patients, results of a six-month Phase 2 clinical trial show. “These top-line results indicate ... Read more

August 14, 2019August 14, 2019

Blood Markers May ID People Most Likely to Gain Cognitively with Aerobic Exercise, Study Reports

News

Blood levels of certain molecules— metabolites and amino acids — may help to identify people with Alzheimer’s disease who are more likely to improve their cognitive skills in response to aerobic ... Read more

August 12, 2019August 12, 2019

AC Immune’s Anti-Tau Vaccine ACI-35.030 to Be Tested in Phase 1b/2a Trial

News

AC Immune is launching a Phase 1b/2a clinical trial to evaluate an investigational anti-tau vaccine called ACI-35.030 as a potential disease-modifying treatment for Alzheimer’s disease and other disorders characterized by ... Read more

Pin It on Pinterest